Safety and Efficacy of APD356 in the Treatment of Obesity
Status:
Completed
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
This is a research study of an investigational drug, APD356, a novel, selective 5-HT2c
receptor agonist, in clinical development as a potential treatment for obesity.
The purpose of this study is to obtain preliminary assessment of the safety and efficacy of
APD356, when administered daily for 28 days, in obese subjects who are otherwise healthy.